Open the filing on EDGARHaemonetics Reports Second Quarter and First Half Fiscal 2027 Results;
Updates Fiscal 2027 Guidance
Boston, MA, November 5, 2026 - Haemonetics Corporation (NYSE: HAE) reported financial results for its second quarter of fiscal 2027, which ended September 26, 2026:
| | 2nd Quarter 2027 | Year-to-Date 2027 |
|---|
| • | Revenue, increase | $358 million, 9% | $697 million, 8% |
| • | Organic revenue increase | 10.0% | 8.0% |
| • | Earnings per diluted share | $1.00 | $1.72 |
| • | Adjusted earnings per diluted share | $1.35 | $2.49 |
| • | Cash flow from operating activities | $128 million | $180 million |
| • | Free cash flow | $104 million | $143 million |
Excludes the impacts of currency fluctuation and the exit of certain liquid solution products.
Chris Simon, Haemonetics’ CEO, stated: “Our second-quarter and first-half results reflect significant momentum across our businesses. Expansion of our CSL relationship and recent innovation milestones in both Apheresis and MedSurg strengthen our competitive position and create powerful new opportunities. With multiple catalysts for growth, we are focused on executing for our customers and translating our momentum into sustained success and shareholder value.”
GAAP RESULTS
Second quarter fiscal 2027 revenue was $357.8 million, up 9.3% compared with the second quarter of fiscal 2026. Business unit revenue and growth rates compared with the prior year period were as follows:
| Second Quarter Fiscal 2027 Reported |
|---|
| (Dollars in Millions) |
|---|
| Apheresis | $204.8 | 12.6% |
| MedSurg | $153.0 | 5.1% |
| Total net revenue | $357.8 | 9.3% |
Gross margin was 61.7% in the second quarter of fiscal 2027, compared with 59.5% in the second quarter of fiscal 2026. The primary drivers of the increase in the gross margin percentage included tariffs refunded, the continued transformation of the product portfolio to higher-margin offerings and the absence of amortization of fair value inventory step-up. Operating expenses were $145.8 million, up $9.5 million, or 7.0%, compared with the second quarter of fiscal 2026. The increase in operating expenses was driven by higher personnel-related costs and freight charges. The Company had operating income of $75.1 million and a 21.0% operating margin in the second quarter of fiscal 2027, compared with operating income of $58.5 million and a 17.9% operating margin in the second quarter of fiscal 2026. The effective income tax rate was 26.3% in the second quarter of fiscal 2027, compared with 24.6% in the second quarter of fiscal 2026. The increase in the effective income tax rate was primarily due to valuation allowances recorded against deferred tax assets in jurisdictions with losses from recent acquisitions. Second quarter fiscal 2027 net income and earnings per diluted share were $46.3 million and $1.00, respectively, compared with $38.7 million and $0.81, respectively, in the second quarter of fiscal 2026.
ADJUSTED RESULTS
Second quarter organic revenue growth was 10.0% compared with the same period of fiscal 2026. Year-over-year organic revenue growth rates by business unit were as follows:
| Second Quarter Fiscal 2027 |
|---|
| Organic |
|---|
| Apheresis | 13.6% |
| MedSurg | 5.5% |
| Total net revenue | 10.0% |
Second quarter fiscal 2027 adjusted gross margin was 61.9%, up 140 basis points compared with the prior year period. The primary drivers of the increase in the adjusted gross margin percentage included tariffs refunded and the continued transformation of the product portfolio to higher-margin offerings, partially offset by foreign currency fluctuations.
Adjusted operating expenses were $127.6 million, up $16.8 million, or 15.2%, compared with the second quarter of fiscal 2026. The increase in adjusted operating expenses was driven by higher personnel-related costs and freight charges. Adjusted operating income for the second quarter of fiscal 2027 was $94.1 million, up $6.8 million, or 7.8%, compared with the second quarter of fiscal 2026. Adjusted operating margin was 26.3%, down 40 basis points when compared with the same period of fiscal 2026. The adjusted income tax rate for the second quarter of fiscal 2027 was 24.7%, which was flat when compared with 24.7% in the second quarter of fiscal 2026.
Second quarter fiscal 2027 adjusted net income was $62.6 million, up $2.3 million, or 3.8%, and adjusted earnings per diluted share was $1.35, up 6.3%, each when compared with the same period of fiscal 2026.
BALANCE SHEET AND CASH FLOW
Cash on hand as of September 26, 2026 was $260.7 million, an increase of $15.3 million since the end of fiscal 2026, primarily driven by cash flow provided from operating activities, partially offset by cash outflows for the repayment of revolving credit facility borrowings, capital expenditures and contingent consideration payments.
Second quarter fiscal 2027 cash flow from operating activities was $128.1 million, up $16.8 million, and free cash flow was $103.8 million, up $15.1 million, each when compared with the same period of fiscal 2026. The primary driver of increased operating cash flow as compared to the same period of fiscal 2026 was favorable working capital adjustments driven by the timing of payments made and cash collections. Free cash flow was impacted by higher capital expenditures, which was partially offset by lower non-cash transfers from Haemonetics equipment.
FISCAL 2027 GUIDANCE
The Company updated its previous fiscal 2027 guidance as follows:
| Total Company |
|---|
| Previous Guidance | Current Guidance |
|---|
| Reported Revenue | 5 - 8% | 8 - 11% |
| 53rd week impact | (~2%) | (~2%) |
| Strategic exits | ~1% | ~1% |
| Currency impact | 0 - 1% | 0 - 1% |
| Organic Revenue | 4 - 7% | 6 - 9% |
| Adjusted operating margin | 50 - 100 bps expansion YoY | 0 - 50 bps expansion YoY |
| Adjusted earnings per diluted share | Comparable to reported revenue growth | Comparable to reported revenue growth |
| Free cash flow conversion | ~80% | >80% |
Includes the impact of the exit of certain liquid solution products.
Previous guidance includes approximately low- to mid-single-digit growth in Apheresis and mid-single digit growth in MedSurg. Current guidance includes high-single-digit growth in Apheresis and mid-single digit growth in MedSurg. Organic growth guidance also includes nominal historical pre-acquisition revenue of Vivasure to provide a comparable view of period-over-period performance.
Free cash flow conversion is calculated as free cash flow divided by adjusted net income.
WEBCAST CONFERENCE CALL AND RESULTS ANALYSIS
The Company will host a conference call with investors and analysts to discuss second quarter fiscal 2027 results on Thursday, November 5, 2026 at 8:00 a.m. ET. The call can be accessed via teleconference at https://register-conf.media-server.com/register/BIf24df80f681345eb86967db309c34804. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.
Alternatively, a live webcast of the call can be accessed on Haemonetics’ investor relations website at the following direct link: https://edge.media-server.com/mmc/p/kf8g7up6.
The Company has also provided a supplemental earnings presentation for its second quarter of fiscal 2027, which is available on its website and can be found at the following direct link: https://haemonetics.gcs-web.com/static-files/96c2477d-9271-40e4-93f2-f3691621b414.
ABOUT HAEMONETICS
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our Apheresis business features proprietary technologies designed to enhance safety, yield, donor satisfaction and operational efficiency for plasma and blood collectors around the world. Our MedSurg business offers Blood Management Technologies to help inform treatment decisions and optimize the management of blood products, and Interventional Technologies, including advanced vascular closure systems and sensor-guided technologies, designed to drive procedural effectiveness and elevate the patient experience. To learn more about Haemonetics, visit www.haemonetics.com.
FORWARD-LOOKING STATEMENTS
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this press release may include, without limitation, statements regarding (i) plans and objectives of management for operations of the Company, including plans or objectives related to the Company’s strategy for growth; product development, commercialization and anticipated benefits; regulatory approvals; the impact of acquisitions and divestitures; market position and expenditures; and the Company’s market and regional alignment initiative; (ii) estimates or projections of future financial results, financial condition, capital expenditures, capital structure or other financial items, including with respect to the Company’s share repurchase program; and (iii) the assumptions underlying or relating to any statement described in points (i) and (ii) above.
Forward-looking statements notice
Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, availability and demand for the Company’s products; the Company’s ability to successfully develop and market new products and technologies; the impact of competitive products and pricing; product quality; disruptions caused by cybersecurity events; any failure to realize the anticipated strategic benefits and opportunities from acquisitions and divestitures; pricing pressures resulting from trends toward healthcare cost containment and the effect of industry consolidation; manufacturing, distribution and supply chain disruptions and cost increases; the Company’s ability to implement as planned and realize estimated cost savings from the market and regional alignment initiative; the effects of global economic and political conditions, including changing trade and tariff policies and inflationary pressures; regulatory uncertainties, including in the receipt or timing of regulatory approvals, and the impact of changes in global regulatory conditions; indebtedness incurred by the Company, including the conditional conversion feature of its convertible notes; the Company’s ability to protect its intellectual property; litigation; and the impact of share repurchases on the Company’s stock price and volatility as well as the effect of short-term price fluctuations on the share repurchase program’s effectiveness. These and other factors are identified and described in more detail in the Company’s periodic reports and other filings with the U.S. Securities and Exchange Commission (the “SEC”). The Company does not undertake to update these forward-looking statements.
MANAGEMENT’S USE OF NON-GAAP MEASURES
This press release contains financial measures that are considered “non-GAAP” financial measures under applicable SEC rules and regulations. Management uses non-GAAP measures to monitor the financial performance of the business, make informed business decisions, establish budgets and forecast future results. Performance targets for management are also based on certain non-GAAP financial measures. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company’s reported financial results prepared in accordance with U.S. GAAP. In this release, supplemental non-GAAP measures have been provided to assist investors in evaluating the performance of the Company’s core operations and provide a baseline for analyzing trends in the Company’s underlying businesses. We strongly encourage investors to review the Company’s financial statements and publicly-filed reports in their entirety and not rely on any single financial measure.
When used in this release, organic revenue growth excludes the impact of currency fluctuation and the exit of certain liquid solution products. Adjusted gross profit, adjusted operating expenses, adjusted operating income, adjusted interest and other income/expense, adjusted provision for income taxes, adjusted net income and adjusted earnings per diluted share exclude restructuring costs, restructuring related costs, digital transformation costs, amortization of acquired intangible assets, amortization of fair value inventory step-up, acquisition and integration related costs, certain tax settlements, unusual or infrequent and material litigation-related charges, equity method losses, impairment of intangible assets and remeasurement of contingent consideration. Adjusted net income and adjusted earnings per diluted share also exclude the tax impact of these items. The adjustments to provision for income taxes are calculated based on the jurisdictions in which pre-tax adjustments occurred. Free cash flow is defined as cash provided by operating activities less capital expenditures and additions to Haemonetics equipment, net of the proceeds from the sale of property, plant and equipment. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures to similarly titled measures used by other companies.
A reconciliation of non-GAAP historical financial measures to their most comparable GAAP measure are included at the end of the financial sections of this press release as well as on the Company’s website at www.haemonetics.com. The Company does not attempt to provide reconciliations of forward-looking adjusted operating margin guidance, adjusted earnings per diluted share guidance or free cash flow conversion guidance to the comparable GAAP measures because the combined impact and timing of recognition of certain potential charges or gains, such as restructuring costs, impairment charges and capital expenditures, is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the Company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of the Company’s financial performance.
| Three Months Ended | Six Months Ended |
|---|
| 9/26/2026 | 9/27/2025 | Inc/(Dec) % | 9/26/2026 | 9/27/2025 | Inc/(Dec) % |
|---|
| (Dollars and Shares in Thousands, Except Per Share Data) | | (Dollars and Shares in Thousands, Except Per Share Data) | |
|---|
| Haemonetics Corporation Financial Summary |
| Condensed Consolidated Statements of Income (Unaudited) |
| Net revenues | | $357,759 | | $327,315 | 9.3% | | $697,139 | | $648,709 | 7.5% |
| Cost of goods sold | | 136,846 | | 132,571 | 3.2% | | 273,423 | | 261,721 | 4.5% |
| Gross profit | | 220,913 | | 194,744 | 13.4% | | 423,716 | | 386,988 | 9.5% |
| Research and development | | 17,029 | | 14,872 | 14.5% | | 33,229 | | 31,133 | 6.7% |
| Selling, general and administrative | | 118,361 | | 101,615 | 16.5% | | 237,302 | | 212,334 | 11.8% |
| Amortization of acquired intangible assets | | 10,403 | | 11,182 | (7.0)% | | 20,607 | | 22,574 | (8.7)% |
| Impairment of intangible assets | | - | | 8,584 | (100.0)% | | - | | 8,584 | (100.0)% |
| Total Operating expenses | | 145,793 | | 136,253 | 7.0% | | 291,138 | | 274,625 | 6.0% |
| Operating income | | 75,120 | | 58,491 | 28.4% | | 132,578 | | 112,363 | 18.0% |
| Interest and other expense, net | | (12,261) | | (7,206) | 70.1% | | (22,145) | | (15,909) | 39.2% |
| Income before provision for income taxes | | 62,859 | | 51,285 | 22.6% | | 110,433 | | 96,454 | 14.5% |
| Provision for income taxes | | 16,554 | | 12,601 | 31.4% | | 31,118 | | 23,739 | 31.1% |
| Net income | | $46,305 | | $38,684 | 19.7% | | $79,315 | | $72,715 | 9.1% |
| Net income per common share assuming dilution | | $1.00 | | $0.81 | 23.5% | | $1.72 | | $1.51 | 13.9% |
| Weighted average shares outstanding | | | | | | |
| Basic | | 45,500 | | 47,590 | | | 45,430 | | 47,850 | |
| Diluted | | 46,463 | | 47,664 | | | 46,084 | | 48,009 | |
| Profit Margins: | | | Inc/(Dec) % | | | Inc/(Dec) % |
| Gross profit | 61.7% | | 59.5% | | 2.2% | 60.8% | | 59.7% | | 1.1% |
| Research and development | 4.8% | | 4.5% | | 0.3% | 4.8% | | 4.8% | | - % |
| Selling, general and administrative | 33.1% | | 31.0% | | 2.1% | 34.0% | | 32.7% | | 1.3% |
| Operating income | 21.0% | | 17.9% | | 3.1% | 19.0% | | 17.3% | | 1.7% |
| Income before provision for income taxes | 17.6% | | 15.7% | | 1.9% | 15.8% | | 14.9% | | 0.9% |
| Net income | 12.9% | | 11.8% | | 1.1% | 11.4% | | 11.2% | | 0.2% |
| Three Months Ended | | | | |
|---|
| 9/26/2026 | 9/27/2025 | Reported growth | Currency impact | Strategic Exits | Organic growth |
|---|
| (Dollars in Thousands) | | | | |
|---|
| Revenue Analysis by Business Unit (Unaudited) |
| Revenues by business unit | | | | | | |
| Plasma | $162,584 | $139,614 | 16.5% | (0.6)% | (0.6)% | 17.7% |
| Other | 42,221 | 42,204 | - % | (0.2)% | - % | 0.2% |
| Apheresis | $204,805 | $181,818 | 12.6% | (0.6)% | (0.4)% | 13.6% |
| Interventional Technologies | $60,508 | $59,073 | 2.4% | (0.8)% | - % | 3.2% |
| Blood Management Technologies | 92,446 | 86,424 | 7.0% | - % | - % | 7.0% |
| MedSurg | $152,954 | $145,497 | 5.1% | (0.4)% | - % | 5.5% |
| Total net revenues | $357,759 | $327,315 | 9.3% | (0.4)% | (0.3)% | 10.0% |
| Six Months Ended | | | | |
| 9/26/2026 | 9/27/2025 | Reported growth | Currency impact | Strategic Exits | Organic growth |
| (Dollars in Thousands) | | | | |
| Revenues by business unit | | | | | | |
| Plasma | $318,108 | $284,688 | 11.7% | (0.3)% | (0.9)% | 12.9% |
| Other | 78,015 | 78,866 | (1.1)% | 0.1% | - % | (1.2)% |
| Apheresis | $396,123 | $363,554 | 9.0% | (0.1)% | (0.7)% | 9.8% |
| Interventional Technologies | $120,450 | $117,556 | 2.5% | (0.5)% | - % | 3.0% |
| Blood Management Technologies | 180,566 | 167,599 | 7.7% | 0.2% | - % | 7.5% |
| MedSurg | $301,016 | $285,155 | 5.6% | (0.1)% | - % | 5.7% |
| Total net revenues | $697,139 | $648,709 | 7.5% | (0.1)% | (0.4)% | 8.0% |
Includes the impact of the exit of certain liquid solution products.
Includes nominal historical pre-acquisition revenue of Vivasure.
Other includes blood collection and processing devices and disposables.
Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines of the MedSurg business unit.
Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the MedSurg business unit.
| September 26, 2026 | March 28, 2026 |
|---|
| (Dollars in Thousands) |
|---|
| Condensed Consolidated Balance Sheets (Unaudited) |
| Assets | | |
| Cash and cash equivalents | $260,712 | $245,440 |
| Accounts receivable, net | 224,952 | 216,855 |
| Inventories, net | 305,006 | 306,370 |
| Other current assets | 64,857 | 66,214 |
| Total current assets | 855,527 | 834,879 |
| Property, plant & equipment, net | 307,921 | 305,761 |
| Intangible assets, net | 426,364 | 447,655 |
| Goodwill | 657,104 | 656,368 |
| Other assets | 163,689 | 151,262 |
| Total assets | $2,410,605 | $2,395,925 |
| Liabilities & Stockholders' Equity | | |
| Short-term debt & current maturities | $9,643 | $5,015 |
| Other current liabilities | 291,195 | 277,584 |
| Total current liabilities | 300,838 | 282,599 |
| Long-term debt | 1,114,118 | 1,219,565 |
| Other long-term liabilities | 97,152 | 97,441 |
| Stockholders' equity | 898,497 | 796,320 |
| Total liabilities & stockholders' equity | $2,410,605 | $2,395,925 |
| Six Months Ended |
|---|
| September 26, 2026 | September 27, 2025 |
|---|
| (Dollars in Thousands) |
|---|
| Condensed Consolidated Statements of Cash Flows (Unaudited) |
| Cash Flows from Operating Activities: | | |
| Net income | $79,315 | $72,715 |
| Adjustments to reconcile net income to net cash provided by operating activities: | | |
| Depreciation and amortization | 54,871 | 57,013 |
| Amortization of fair value inventory step-up | - | 4,491 |
| Share-based compensation expense | 19,539 | 16,901 |
| Impairment of intangible assets | - | 8,584 |
| Deferred income taxes | 3,234 | (3,956) |
| Change in other non-cash operating activities | 5,389 | 2,361 |
| Change in operating assets and liabilities: | | |
| Change in accounts receivable, net | (8,064) | (3,702) |
| Change in inventories, net | 978 | 25,058 |
| Change in prepaid income taxes | 2,428 | 3,136 |
| Change in other assets and other liabilities | (18,277) | (23,688) |
| Change in accounts payable and accrued expenses | 41,010 | (30,197) |
| Net cash provided by operating activities | 180,423 | 128,716 |
| Cash Flows from Investing Activities: | | |
| Capital expenditures | (22,677) | (8,770) |
| Non-cash transfers from inventory to property, plant and equipment for Haemonetics equipment | (15,657) | (29,149) |
| Proceeds from sale of property, plant and equipment | 813 | 417 |
| Other investments | (9,000) | (25,966) |
| Net cash used in investing activities | (46,521) | (63,468) |
| Cash Flows from Financing Activities: | | |
| Repayments, net of borrowings | (103,125) | (3,125) |
| Share repurchases | - | (75,000) |
| Contingent consideration payments | (17,597) | - |
| Proceeds from employee stock programs | 5,500 | 4,001 |
| Cash used to net share settle employee equity awards | (3,888) | (4,795) |
| Other financing activities | (29) | (75) |
| Net cash used in financing activities | (119,139) | (78,994) |
| Effect of exchange rates on cash and cash equivalents | 509 | 3,409 |
| Net Change in Cash and Cash Equivalents | 15,272 | (10,337) |
| Cash and Cash Equivalents at Beginning of the Period | 245,440 | 306,763 |
| Cash and Cash Equivalents at End of Period | $260,712 | $296,426 |
| Free Cash Flow Reconciliation: | | |
| Cash provided by operating activities | $180,423 | $128,716 |
| Capital expenditures | (22,677) | (8,770) |
| Additions to Haemonetics equipment | (15,657) | (29,149) |
| Proceeds from sale of property, plant and equipment | 813 | 417 |
| Free cash flow | $142,902 | $91,214 |
| Gross profit | Operating expenses | Operating income | Interest and other (expense) income | Provision (benefit) for income taxes | Net income (loss) | Earnings per diluted share |
|---|
| Reconciliation of Adjusted Measures for Second Quarter of FY27 and FY26 (Unaudited) |
| Three Months Ended September 26, 2026: | (Dollars in Thousands, Except Per Share Data) |
| Reported | | $220,913 | | $145,793 | | $75,120 | $(12,261) | $16,554 | | $46,305 | $1.00 |
| Amortization of acquired intangible assets | | - | | (10,403) | | 10,403 | - | 2,160 | | 8,243 | 0.18 |
| Integration and transaction costs | | 924 | | (1,627) | | 2,551 | (2) | 91 | | 2,458 | 0.05 |
| Restructuring costs | | (219) | | 7 | | (226) | - | (35) | | (191) | - |
| Restructuring related costs | | 11 | | - | | 11 | - | - | | 11 | - |
| Digital transformation costs | | - | | (5,405) | | 5,405 | - | 1,305 | | 4,100 | 0.09 |
| Litigation-related charges | | - | | (44) | | 44 | - | - | | 44 | - |
| Remeasurement of contingent consideration | | - | | (748) | | 748 | - | 161 | | 587 | 0.01 |
| Equity method losses | | - | | - | | - | 1,354 | 333 | | 1,021 | 0.02 |
| Discrete tax items | | - | | - | | - | - | 1 | | (1) | - |
| Adjusted | | $221,629 | | $127,573 | | $94,056 | $(10,909) | $20,570 | | $62,577 | $1.35 |
| Adjusted, as a percentage of net revenues | 61.9% | | 35.7% | | 26.3% | | | | 17.5% | | |
| Gross profit | Operating expenses | Operating income (loss) | Interest and other expense | Provision (benefit) for income taxes | Net income (loss) | Earnings per diluted share |
| Three Months Ended September 27, 2025: | (Dollars in Thousands, Except Per Share Data) |
| Reported | | $194,744 | | $136,253 | | $58,491 | $(7,206) | $12,601 | | $38,684 | $0.81 |
| Amortization of acquired intangible assets | | - | | (11,182) | | 11,182 | - | 2,810 | | 8,372 | 0.19 |
| Amortization of fair value inventory step-up | | 2,055 | | - | | 2,055 | - | 505 | | 1,550 | 0.03 |
| Integration and transaction costs | | 1,336 | | (183) | | 1,520 | - | 387 | | 1,133 | 0.02 |
| Restructuring costs | | (142) | | (346) | | 204 | - | 75 | | 129 | - |
| Restructuring related costs | | 38 | | (16) | | 54 | - | 12 | | 42 | - |
| Digital transformation costs | | - | | (5,054) | | 5,054 | - | 1,236 | | 3,818 | 0.08 |
| Litigation-related charges | | - | | (220) | | 220 | - | 53 | | 167 | - |
| Impairment of intangible assets | | - | | (8,584) | | 8,584 | - | 2,147 | | 6,437 | 0.14 |
| Remeasurement of contingent consideration | | - | | 87 | | (87) | - | (57) | | (30) | - |
| Adjusted | | $198,031 | | $110,755 | | $87,277 | $(7,206) | $19,769 | | $60,302 | $1.27 |
| Adjusted, as a percentage of net revenues | 60.5% | | 33.8% | | 26.7% | | | | 18.4% | | |
| Gross profit | Operating expenses | Operating income (loss) | Interest and other (expense) income | Provision (benefit) for income taxes | Net income (loss) | Earnings per diluted share |
|---|
| Reconciliation of Adjusted Measures for Year-to-Date of FY27 and FY26 (Unaudited) |
| Six Months Ended September 26, 2026: | (Dollars in Thousands, Except Per Share Data) |
| Reported | | $423,716 | | $291,138 | | $132,578 | $(22,145) | $31,118 | | $79,315 | $1.72 |
| Amortization of acquired intangible assets | | - | | (20,607) | | 20,607 | - | 4,445 | | 16,162 | 0.35 |
| Integration and transaction costs | | 2,209 | | (3,108) | | 5,317 | (2) | (326) | | 5,641 | 0.12 |
| Restructuring costs | | 564 | | (1,508) | | 2,072 | - | 502 | | 1,570 | 0.03 |
| Restructuring related costs | | 21 | | 50 | | (29) | - | - | | (29) | - |
| Digital transformation costs | | - | | (11,568) | | 11,568 | - | 2,868 | | 8,700 | 0.19 |
| Litigation-related charges | | - | | (501) | | 501 | - | - | | 501 | 0.01 |
| Remeasurement of contingent consideration | | - | | (701) | | 701 | - | 156 | | 545 | 0.01 |
| Equity method losses | | - | | - | | - | 2,354 | 588 | | 1,766 | 0.04 |
| Discrete tax items | | - | | - | | - | - | (695) | | 695 | 0.02 |
| Adjusted | | $426,510 | | $253,195 | | $173,315 | $(19,793) | $38,656 | | $114,866 | $2.49 |
| Adjusted, as a percentage of net revenues | 61.2% | | 36.3% | | 24.9% | | | | 16.5% | | |
| Gross profit | Operating expenses | Operating income (loss) | Interest and other (expense) income | Provision (benefit) for income taxes | Net income (loss) | Earnings per diluted share |
| Six Months Ended September 27, 2025: | (Dollars in Thousands, Except Per Share Data) |
| Reported | | $386,988 | | $274,625 | | $112,363 | $(15,909) | $23,739 | | $72,715 | $1.51 |
| Amortization of acquired intangible assets | | - | | (22,574) | | 22,574 | - | 5,733 | | 16,841 | 0.36 |
| Amortization of fair value inventory step-up | | 4,491 | | - | | 4,491 | - | 1,123 | | 3,368 | 0.07 |
| Integration and transaction costs | | 2,366 | | (1,836) | | 4,202 | 2,022 | 1,599 | | 4,625 | 0.10 |
| Restructuring costs | | (526) | | (1,997) | | 1,470 | - | 365 | | 1,105 | 0.02 |
| Restructuring related costs | | 24 | | (87) | | 112 | - | 21 | | 91 | - |
| Digital transformation costs | | - | | (10,409) | | 10,409 | - | 2,570 | | 7,839 | 0.16 |
| Litigation-related charges | | - | | (804) | | 804 | - | 201 | | 603 | 0.01 |
| Impairment of intangible assets | | - | | (8,584) | | 8,584 | - | 2,147 | | 6,437 | 0.13 |
| Remeasurement of contingent consideration | | - | | 180 | | (180) | - | (91) | | (89) | - |
| Adjusted | | $393,343 | | $228,514 | | $164,829 | $(13,887) | $37,407 | | $113,535 | $2.36 |
| Adjusted, as a percentage of net revenues | 60.6% | | 35.2% | | 25.4% | | | | 17.5% | | |
Contacts
Olga Guyette, Vice President-Investor Relations & Treasury · (781) 356-9763 · olga.guyette@haemonetics.com · David Trenk, Sr. Manager-Investor Relations · (203) 733-4987 · david.trenk@haemonetics.com
Media Contact · Josh Gitelson, Sr. Director-Global Communications · (781) 356-9776 · josh.gitelson@haemonetics.com